Abstract
How BMP signaling integrates into and destabilizes the pluripotency circuitry of human pluripotent stem cells (hPSCs) to initiate differentiation into individual germ layers is a long-standing puzzle. Here we report muscle segment homeobox 2 (MSX2), a homeobox transcription factor of msh family, as a direct target gene of BMP signaling and a master mediator of hPSCs' differentiation to mesendoderm. Enforced expression of MSX2 suffices to abolish pluripotency and induce directed mesendoderm differentiation of hPSCs, while MSX2 depletion impairs mesendoderm induction. MSX2 is a direct target gene of the BMP pathway in hPSCs, and can be synergistically activated by Wnt signals via LEF1 during mesendoderm induction. Furthermore, MSX2 destabilizes the pluripotency circuitry through direct binding to the SOX2 promoter and repression of SOX2 transcription, while MSX2 controls mesendoderm lineage commitment by simultaneous suppression of SOX2 and induction of NODAL expression through direct binding and activation of the Nodal promoter. Interestingly, SOX2 can promote the degradation of MSX2 protein, suggesting a mutual antagonism between the two lineage-specifying factors in the control of stem cell fate. Together, our findings reveal crucial new mechanisms of destabilizing pluripotency and directing lineage commitment in hPSCs.
Similar content being viewed by others
Introduction
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) derived from the inner cell mass (ICM) or human induced pluripotent stem cells reprogrammed from somatic cells, can self-renew almost indefinitely in culture and have the remarkable potential to differentiate into nearly all cell types in the human body1,2. They therefore hold great promise for developmental studies, drug screening, cell-based therapy and disease modeling. Harnessing the full potential of hPSCs requires a deeper understanding of the signaling mechanisms governing pluripotency and directed differentiation into the early embryonic lineages3,4.
Significant advances have been made towards the understanding of the extrinsic growth factors, intracellular pathways and nuclear factors united to control pluripotency and self-renewal of hPSCs. Basic FGF (bFGF), IGF and TGF-β/Activin/Nodal cooperate to support pluripotency by stabilizing the core transcriptional circuitry consisting of OCT4 (also known as POU5F1), SOX2 and NANOG, which function in concert to positively regulate target genes necessary for pluripotency and to repress a variety of lineage specification factors5,6,7,8. Signals from the extrinsic factors are integrated and transmitted by cytoplasmic pathways including PI3K, MAPK/ERK, Smads and mammalian target of rapamycin (mTOR), which support the undifferentiated state of hPSCs6,9,10,11.
In contrast to our understanding of the factors that govern pluripotency, molecular program that controls hPSC exit from pluripotency and entry into the embryonic germ layers is still poorly defined. The Wnt/β-catenin and BMP signaling pathways are critical for hPSC differentiation into the early embryonic lineages. Activation of Wnt signaling results in a loss of pluripotency and drives hPSC differentiation towards endoderm and mesoderm12,13,14, and activation of BMP signaling leads to mesendoderm or trophoectoderm differentiation, depending on the dose and duration of stimulation15,16. Interestingly, Nodal/Activin signaling cooperates with bFGF to maintain pluripotency17,18, but promotes mesendoderm differentiation of hESCs in the absence of bFGF19,20,21. Despite these studies, there are still significant gaps in the knowledge of the signaling mechanisms that regulate cell fate transitions from pluripotency to the embryonic germ layers. Especially, the intracellular and nuclear factors that mediate hPSC mesendoderm differentiation, the direct target gene(s) of BMP signaling that mediate BMP's function in mesendoderm induction, and how they interact with and destabilize the core pluripotency circuitry and induce mesendoderm lineage commitment remain to be defined.
By taking advantage of a high-efficiency neural induction model and large-scale gene profiling analysis, we previously identified muscle segment homeobox (MSX2) as a responsive gene to BMP stimulation in hPSCs22. This finding was subsequently confirmed in a separate study23. MSX2, a homeobox-containing transcription factor, belongs to the highly conserved and widely expressed msh family24,25,26. MSX2 has been described as a transcription repressor, but emerging evidence suggests that it can also activate downstream target genes27,28. Experiments in mouse model have revealed an essential function for Msx2 in craniofacial, limb and ectodermal organogenesis — Msx2 deletion mutations result in profound defects in the development of skull vault, tooth, hair follicle and mammary gland26,29. In keeping with the defects in mice, mutations of MSX2 are associated with Boston-type craniosynostosis and parietal foramina30,31,32,33. The function of MSX2 in craniofacial, limb and mammary gland development is linked to its ability to regulate epithelial to mesenchymal transition26,34,35,36. Despite the knowledge of MSX2 involvement in BMP signaling and organogenesis, the role of MSX2 in early embryonic development, especially in human, remains to be elucidated.
In this study, we explored the function of MSX2 in hPSC fate determination, revealing an essential role of MSX2 in hPSCs' exit from pluripotency and entry to mesendoderm. MSX2 is both necessary and sufficient for mesendoderm differentiation of hPSCs. MSX2 acts as a direct target gene of the BMP pathway in hPSCs, and it can be synergistically activated by Wnt signals via LEF1 during mesendoderm differentiation. Furthermore, MSX2 destabilizes the pluripotency circuitry through direct binding to the SOX2 promoter and repression of SOX2 transcription, while MSX2 induction of mesendoderm differentiation requires simultaneous suppression of SOX2 and activation of Nodal signaling. Interestingly, SOX2 does not merely lie downstream of MSX2 but can promote the MSX2 protein degradation, suggesting a mutual antagonism between these two factors in the control of stem cell fate.
Results
Enforced MSX2 expression induces directed hESC mesendoderm differentiation
To explore the function of MSX2 in fate determination of hPSCs, we overexpressed MSX2 in hESCs using a previously described doxcycline (DOX) inducible lentiviral expression system and assessed its effect37. We used a GFP-MSX2 fusion gene which allowed us to monitor its expression in hESCs in real time (Supplementary information, Figure S1A). As expected, GFP expression was largely undetectable in the absence of DOX but could be readily seen 24 h after DOX was added (Supplementary information, Figure S1B). A high percentage of GFP-MSX2-positive cells were detected after colony isolation and drug selection (90.8% ± 5.1%; Supplementary information, Figure S1B).
MSX2 overexpression induced profound morphological changes in hESCs. 72 h after DOX was added, hESCs began to flatten and spread out. After 120 h, the colony integrity of hESCs was completely abolished; instead, large flat cells formed a uniform layer (Figure 1A). The alterations in hESC morphology suggested an induction of differentiation. Indeed, real-time PCR analysis revealed a rapid downregulation of pluripotency marker SOX2, while expression of POU5F1/OCT4 and NANOG, which was unaltered or moderately elevated at 24 h, decreased gradually (Figure 1B). Concomitant with the downregulation of pluripotency markers, expression of mesendoderm markers T (also known as BRACHYURY) and MIXL1 increased dramatically, peaking at 72 h after DOX addition (Figure 1B). In contrast, neuroectoderm markers PAX6 and SOX1 were substantially downregulated (Figure 1B). The effect of MSX2 overexpression on pluripotency and differentiation marker expression was confirmed at the protein level by western blotting and immunofluorescence analysis (Figure 1C; Supplementary information, Figure S1C). Strikingly, T was found in nearly all GFP-MSX2-overexpressing cells, while no PAX6 and SOX1 expression was detected (Figure 1C). Furthermore, GFP-MSX2-overexpressing hESCs could no longer form teratomas in vivo, in sharp contrast to cells that overexpressed GFP only (Figure 1D), indicating that hESCs with MSX2 overexpression lost the potential to differentiate into three germ layers, a hallmark of pluripotency. The effects of MSX2 overexpression were observed in H1 hESCs cultured in mTeSR1 medium, E8 medium, and mouse embryonic fibroblast (MEF)-conditioned medium (CM), suggesting conserved MSX2 effect under various culture conditions (Supplementary information, Figure S1C). Furthermore, MSX2 overexpression also induced mesendoderm differentiation in H9 hESCs, suggesting conserved responses in hPSCs (Supplementary information, Figure S1D). Thus, enforced MSX2 expression suffices to abolish pluripotency and induce directed mesendoderm differentiation in hPSCs.
Previous report that MSX1 can respond to BMP signaling activation38,39, led us to also assess the effect of MSX1 overexpression in hESCs (Supplementary information, Figure S1E). While profound morphological changes could also be observed 120 h after DOX addition, the upregulation of T and MIXL1 mRNA levels was much lower than that caused by MSX2 overexpression (Supplementary information, Figure S1F). Moreover, enforced expression of MSX1 did not repress expression of neuroectoderm markers such as PAX6 and SOX1 (Supplementary information, Figure S1F). These results indicate that MSX2 is much more potent than MSX1 in inducing directed mesendoderm differentiation of hESCs.
MSX2 is required for hPSCs' exit from pluripotency and entry to mesendoderm lineage
We next asked whether MSX2 was required for mesendoderm differentiation of hPSCs. We induced directed mesendoderm differentiation using a previously described protocol with some modifications40 (Supplementary information, Figure S2A). The presence of Activin A, BMP4, Wnt3a and bFGF induced H1 hESCs to adopt a differentiation morphology (Supplementary information, Figure S2B) and increased the expression of mesendoderm markers including T, MIXL1 and others (Supplementary information, Figure S2C). Time-course analysis revealed a rapid, time-dependent upregulation of both MSX2 mRNA and protein upon induction of differentiation (Figure 2A, Supplementary information, Figure S2D). MSX1 was also upregulated, but the increase was much less and slower than MSX2. During spontaneous differentiation of hPSCs induced via embryoid body (EB) formation, MSX2 expression was also upregulated within 24-48 h and peaked at 72-96 h. In contrast, MSX1 expression remained at a very low level up to 120 h (Figure 2B). Thus, we mainly focused on MSX2 in the rest of the study.
We first used small hairpin RNAs (shRNAs) to deplete MSX2 in hESCs and determined the impact on mesendoderm differentiation. MSX2 depletion in H1 hESCs under self-renewal condition (i.e., in mTeSR1 medium) had minimal effect, presumably due to the low expression level of MSX2 (Figure 2C-0 h, Supplementary information, Figure S3A-0 h). Strikingly, upon induction of mesendoderm differentiation, cells depleted of MSX2 exhibited much lower levels of T mRNA and protein than control cells (Figure 2C, Supplementary information, Figure S3B). In addition, expression of other mesendoderm markers such as MIXL1, GATA4 and GATA6 was also significantly reduced (Figure 2C). In contrast, levels of pluripotency marker POU5F1/OCT4, neuroectoderm markers PAX6 and SOX1, and neuroectoderm/pluripotency marker SOX2 were substantially elevated (Supplementary information, Figure S3A and S3B). Impairment of mesendoderm differentiation upon MSX2 depletion was also observed in H9 hESCs (Supplementary information, Figure S3C and S3D). Unexpectedly, the pluripotency marker NANOG was repressed upon MSX2 depletion in both H1 and H9 hESCs (Supplementary information, Figure S3A-S3D). We speculated that this might be related to NANOG function in suppressing neural differentiation and in patterning different subtypes of mesoderm cells after exit of hESCs from pluripotency, as described previously41,42. To further confirm the role of MSX2 in hESC early differentiation and exclude the potential ambiguity brought by shRNAs, we deleted MSX2 gene in hESCs using CRISPR-CAS9 technology. We designed two sgRNAs each targeting a separate exon in human MSX2 gene, using a previously described method43 (Supplementary information, Figure S4A). Gene sequencing and western blotting analysis confirmed the establishment of two homozygous H1 hESC lines with MSX2 deletion (MSX2−/− 1# and MSX2−/− 2#; Figure 2D, Supplementary information, Figure S4B). We induced both directed and spontaneous mesendoderm differentiation of these two knock-out hESC lines. Consistent with the results by using shRNAs, MSX2 deletion significantly reversed the differentiation morphology of hESCs and inhibited mesendoderm marker expression (Figure 2E). Furthermore, compared with the EBs derived from wild-type hESCs, MSX2-deleted EBs had a much low level of T expression, while neuroectoderm markers PAX6 and SOX1 and neuroectoderm/pluripotency marker SOX2 were substantially upregulated (Figure 2F). These results suggest that EBs with MSX2 deletion has a strong bias toward neuroectoderm differentiation at the expense of mesendoderm differentiation. Interestingly, in MSX2-deleted EBs, MSX1 level was enhanced, presumably due to compensatory mechanism25,44,45 (Figure 2F). Together, these findings confirm the essential role of MSX2 in hPSC mesendoderm differentiation.
MSX2 is a direct target of BMP signaling in hESCs
MSX2 is a component of multiple developmental pathways including BMP, Wnt and FGF23,27,46,47. During mesendoderm differentiation of hESCs, MSX2 is rapidly upregulated in the presence of Activin A, BMP4, Wnt3a and bFGF, leading us to ask which of the extrinsic factors could induce MSX2 expression. As expected, stimulation of hESCs with BMP4 led to a rapid and dramatic upregulation of MSX2 mRNA within 3 h of BMP4 stimulation (Figure 3A and Supplementary information, Figure S4C). Furthermore, induction of MSX2 expression consistently preceded T and CDX2 — two previously reported BMP4 targets in hESCs48 (Figure 3A and Supplementary information, Figure S4C). In contrast, treatment of cells with Activin A, Wnt3a, bFGF and other factors caused little effect on MSX2 and MSX1 expression (Figure 3B). Interestingly, combination BMP4 and Wnt3a led to a synergistic stimulation of MSX2 expression, while the combination of BMP4 with other factors failed to cause additive effect (Figure 3C).
It was previously reported that MSX2 promoter contains a 52 bp phylogenetically conserved BMP-restricted Smad-binding element termed BMP-responsive element (BMPre; Supplementary information, Figure S4D)49,50. Binding of Smads such as Smad1 to this site has been observed in mouse cells49. We conducted chromatin immunoprecipitation coupled to detection by quantitative real-time PCR (ChIP-qPCR) to examine whether BMP-restricted SMADs were capable of binding to BMPre in hESCs. Indeed, our results indicated there was strong binding of phosphorylated (activated) Smad1 to this site in hESCs (Figure 3D). To further explore whether BMP activation of MSX2 requires a binding to the Smad1 binding sites of BMPre within MSX2 promoter, we isolated the 2 kb fragment containing BMPre within the MSX2 promoter and tested its response to BMP stimulation using a luciferase-based reporter assay. We found that BMP stimulation enhanced the activity of BMPre in hESCs in a dose-dependent manner (Figure 3E). Thus, BMP signaling directly activates MSX2.
We have shown that BMP and Wnt activation can synergistically activate MSX2. It has been previously reported that LEF1, a transcriptional mediator of Wnt signaling, interacts with Smad1 and Smad4 to regulate graded expression of Msx2 in mouse ESCs51. We thus tested whether LEF1 was also involved in induction of MSX2 expression by Wnt signaling in hESCs. We found enforced expression of LEF1 enhanced MSX2 expression synergistically with BMP treatment (Figure 3F). Moreover, the luciferase activity of BMPre within the MSX2 promoter could be further enhanced by co-transfection of Smad1, Smad4 and LEF1 (Figure 3G). Thus, LEF1 acts as a key factor that mediates the function of Wnt signaling in MSX2 activation.
Taken together, our data suggest that MSX2 serves as a master mediator of hPSCs exit from pluripotency and entry to the mesendoderm fate.
MSX2 suppresses SOX2 via directly binding to SOX2 promoter
How does MSX2 induce mesendoderm differentiation of hESCs? Notably, MSX2 overexpression in hESCs led to the differential expression of a number of cell fate-specifying factors (Figure 1B). Among them, the decrease in SOX2 expression appeared rapid and dramatic (Figure 1B; Supplementary information, Figure S1C and S1D). SOX2 is an integral component of the core transcriptional circuitry of pluripotency and also plays an essential role in neuroectoderm specification of hPSCs52,53. Depletion of SOX2 in hPSCs disrupts pluripotency and induces mesendoderm activities, reminiscent of MSX2 overexpression54,55. We thus asked whether SOX2 is a downstream target of MSX2 in mesendoderm differentiation.
We examined SOX2 response in the first 24 h of MSX2 overexpression. 3 h after the addition of DOX, an increase in MSX2 mRNA level was detected (Figure 4A). Strikingly, a concomitant decrease in SOX2 mRNA level was also seen at this time point. As MSX2 level continued to increase at later time points, the decrease in SOX2 level became more drastic (Figure 4A). Furthermore, the negative regulation of SOX2 by MSX2 was seen in a DOX dose-dependent manner (Figure 4B). In contrast, the levels of POU5F1/OCT4 and NANOG were largely unaltered or slightly increased (Figure 4A and 4B). Thus, SOX2 might serve as a direct target of MSX2 in hPSCs during mesendoderm differentiation.
To support this hypothesis, we isolated SOX2 5′ flanking sequences of various lengths (0.5, 1 and 2 kb) and tested their responses to enforced MSX2 expression using luciferase reporter assay. Indeed, all three SOX2 promoter fragments responded to MSX2 overexpression by decreasing the luciferase activity (Supplementary information, Figure S4E). Because no significant difference was observed among the three fragments, we used the 0.5 kb promoter fragment for subsequent analysis.
We found that MSX2 overexpression significantly reduced activity of SOX2 promoter both in HEK293T cells (Figure 4C) and in NTERA-2 cells (a human pluripotent embryonal carcinoma cell line; Figure 4D) in a dose-dependent manner (Supplementary information, Figure S4F). In contrast, MSX1 overexpression had minimal effect on SOX2 promoter activity (Supplementary information, Figure S4G). Bioinformatics analysis identified three potential MSX2 binding sequences (MBS1-3) within the 2 kb SOX2 promoter region56 (Figure 4E). In addition to the MBSs, we also included two previously reported SOX2 transcription enhancer sequences57 in our analysis (designated as SRR1 and SRR2; Figure 4E). ChIP-qPCR in H1 hESCs revealed that MSX2 bound to MBS2 and MBS3, but not MBS1, SRR1 or SRR2 (Figure 4F).
We next asked whether MSX2 binding to MBS2 and MBS3 was responsible for suppression of SOX2 transcription. By using site-directed mutagenesis, we generated mutations in MBS2 and MBS3, separately or together (Supplementary information, Figure S4H), and found that MSX2 suppression of SOX2 promoter activity was substantially attenuated, especially when both MBS2 and MBS3 were mutated (Figure 4G). In keeping with the effect of mutations, deletion of MBS2 and MBS3 also impaired MSX2 suppression of SOX2 (Supplementary information, Figure S4I). Together, these data indicate that MSX2 suppresses SOX2 expression by directly binding to and inhibiting SOX2 promoter.
MSX2 suppression of SOX2 is linked to its mesendoderm-inducing function
We next asked whether MSX2 suppression of SOX2 is linked to its function in mesendoderm induction. To this end, we created two MSX2 mutants: MSX2-T147A and MSX2-P148H, which can reduce and enhance DNA binding activities, respectively28 (Figure 5A). Surprisingly, both mutants exhibited normal binding activities to MBS2 and MBS3 in SOX2 promoter and were still capable of inhibiting SOX2 promoter activity and suppressing SOX2 expression (Figure 5B and Supplementary information, Figure S5A). Consistently, overexpression of these mutants induced hESCs to undergo mesendoderm differentiation (Figure 5C and 5D, Supplementary information, Figure S5A and S5B).
We next generated another MSX2 mutant containing a deletion (Δ132-148; Figure 5A) within the homeodomain that carries core suppressor function of MSX228,58. In contrast to the T147A and P148H mutants, the MSX2-Δ132-148 mutant failed to bind to MBS2 and MBS3 (Supplementary information, Figure S5C) and could not inhibit SOX2 promoter activity or induce mesendoderm differentiation of hESCs (Figure 5B-5D). We noticed that the expression level of MSX2-Δ132-148 was slightly lower than the other two mutants (Supplementary information, Figure S5B). To exclude the possibility that the lack of function was due to low expression, we induced MSX2-Δ132-148 expression using different concentrations of DOX, which led to a dose-dependent increase of MSX2-Δ132-148 protein (Supplementary information, Figure S5D and S5E). There was no induction of mesendoderm differentiation even with a high DOX concentration (4 μg/ml; Figure 5C, 5D and Supplementary information, Figure S5E). In addition, prolonged induction of MSX2-Δ132-148 expression (for 120 h) also failed to induce mesendoderm differentiation of hESCs, suggesting that the lack of effect was not due to a slower response (Supplementary information, Figure S5F).
Mutual antagonism between SOX2 and MSX2
Having established that MSX2 inhibits SOX2 expression by directly binding to SOX2 promoter, we investigated the possibility that SOX2 might also suppress MSX2 level based on the following correlative evidence. First, SOX2 is highly expressed in hESCs under self-renewal condition, while MSX2 is almost undetectable. Second, in hESCs induced to undergo neural differentiation, SOX2 remains at a high level, but MSX2 expression is continuously suppressed.
We first asked whether enforced SOX2 expression could reduce the level of MSX2 and rescue MSX2-induced hESCs mesendoderm differentiation. We fused SOX2 to mKate, a red fluorescence protein, and expressed the chimeric gene in cells overexpressing MSX2. Remarkably, enforced expression of SOX2 nearly completely rescued the effect caused by MSX2 expression: cells with SOX2 overexpression exhibited colony morphologies highly reminiscent of those of normal hESCs (Figure 6A). The rescue effect appeared specific for SOX2: enforced expression of OCT4 failed to reverse MSX2-induced morphological changes (Supplementary information, Figure S6A). At the molecular level, SOX2 overexpression prevented the upregulation of mesendoderm markers such as T and MIXL1, as determined by real-time PCR and western blotting analyses (Figure 6B and 6C). Although OCT4 overexpression attenuated T upregulation induced by MSX2, it failed to rescue expression of the pluripotency markers SOX2, endogenous POU5F1/OCT4 and NANOG, which was even further downregulated (Supplementary information, Figure S6B). Strikingly, SOX2 overexpression also significantly impaired enforced expression of MSX2, as shown by a substantial reduction in the level of GFP-MSX2 protein (Figure 6C). Interestingly, despite the reduced level of GFP-MSX2, the MSX2 mRNA level remained largely unaltered (Figure 6B), implying that SOX2 regulation of MSX2 occurs post-transcriptionally. Indeed, it has been reported that the presence of MSX2-P148H mutant causes higher susceptibility to ubiquitin-dependent degradation of wild-type MSX2 protein59, implying protein degradation as a potential regulatory mechanism of MSX2 expression.
We explored how SOX2 overexpression might lead to decreased MSX2 protein level. First, in both HEK293T cells and hESCs, expression of SOX2 decreased the level of MSX2 in a dose- and time-dependent manner (Supplementary information, Figure S6C and S6D). In contrast, SOX2 overexpression failed to decrease the level of the MSX2-Δ132-148 mutant protein (Supplementary information, Figure S6E). Next, to examine whether SOX2 promotes the degradation of MSX2 protein, we assessed the half-life of MSX2 in the presence of protein synthesis inhibitor cycloheximide. As shown in Figure 6D and Supplementary information, Figure S6F, the half-life of MSX2 was slightly reduced in control cells without SOX2 overexpression, and was substantially reduced with SOX2 overexpression. Furthermore, because intracellular protein turnover is primarily mediated by proteasomal degradation, we treated H1 hESCs with MG132, a potent inhibitor of the proteasome. MG132 slightly increased the level of MSX2 protein in the absence of SOX2 overexpression, but almost completely rescued the reduction of MSX2 protein caused by SOX2 overexpression (Figure 6E). Thus, SOX2 promotes MSX2 protein degradation via the proteasome pathway.
Taken together, our results a reveal mutual antagonism between MSX2 and SOX2 in hPSCs. SOX2 does not merely act downstream of MSX2 but can also destabilize MSX2 protein. This mutual antagonism likely plays a significant role in fate decisions of hPSCs.
Nodal signaling is an essential downstream effector of MSX2
We have showed that MSX2 overexpression leads to rapid downregulation of SOX2 in hESCs (Figures 1B, 4A and 4B). If SOX2 downregulation is solely responsible for MSX2 induction of mesendoderm differentiation, SOX2 depletion in hESCs should mimic the effects of MSX2 enforced expression. Interestingly, we found that although SOX2 depletion disrupted pluripotency and induced mesendoderm activities in hESCs, the upregulation of mesendoderm markers upon SOX2 depletion was much less rapid and drastic than enforced MSX2 expression (Supplementary information, Figure S7A). These results are consistent with an earlier study54. We therefore inferred that additional pathway(s) might mediate the function of MSX2 in mesendoderm induction.
To discover additional MSX2 downstream effectors, we conducted whole genome RNA sequencing (RNA-seq) in hESCs after induction of MSX2 expression. We focused our analysis on early time points (0, 12, 24, 48 and 72 h) after the addition of DOX to reveal potential immediate downstream targets of MSX2. Among the genes with significantly altered expression, NODAL, a member of the TGF-β superfamily, was rapidly (within 12 h) and drastically upregulated after MSX2 induction, and stayed at a high level until 48 h (Figure 7A). The Activin/Nodal signaling pathway is essential for early embryonic development and plays a critical role in mesendoderm differentiation of hPSCs17,21, leading us to hypothesize that Nodal signaling is involved in MSX2 induction of mesendoderm differentiation.
Indeed, MSX2 overexpression upregulated NODAL at both the mRNA and protein levels in hESCs (Figure 7B, Supplementary information, Figure S7B). Interestingly, the MSX2-Δ132-148 mutant, which fails to induce mesendoderm differentiation, also failed to induce the upregulation of NODAL (Supplementary information, Figure S7C). To test the role of NODAL in hESC early differentiation, we used Nodal inhibitor LEFTY-A and found it inhibited MSX2-induced upregulation of mesendoderm markers in a dose-dependent manner (Figure 7C). Similarly, SB-431542, a commonly used chemical inhibitor of TGF-β receptors, also prevented MSX2-induced mesendoderm differentiation (Supplementary information, Figure S7D). NODAL addition to hESCs under self-renewal condition was insufficient to disrupt pluripotency or induce differentiation, in keeping with previously documented function of NODAL in supporting pluripotency8,17. However, NODAL addition to hESCs depleted of SOX2 significantly increased the expression of mesendoderm markers over the level of SOX2 depletion alone (Figure 7D, Supplementary information, Figure S7E). Thus, NODAL in conjunction with SOX2 depletion mimics the effect of enforced MSX2 expression in hESCs, suggesting that SOX2 and NODAL are essential downstream effectors of MSX2.
Interestingly, it has been reported that BMP, Wnt and NODAL can regulate each other and form a signaling loop essential for early lineage specification of mouse and human embryonic stem cells60,61,62. In this study we have shown that MSX2 acts as a direct target gene of BMP4, while Wnt signaling activates MSX2 expression synergistically with BMP. We therefore asked whether MSX2 is involved in BMP and Wnt regulation of NODAL. Indeed, BMP4 and Wnt3a treatment elevated the expression of MSX2, NODAL and T (Figure 7E). Depletion of MSX2 significantly repressed NODAL and T upregulation (Figure 7F, Supplementary information, Figure S8A). Our data suggest that NODAL is a downstream target of MSX2 through BMP and Wnt.
To further explore the mechanism by which MSX2 activates NODAL expression, we isolated 5 kb NODAL 5′ flanking sequences and tested its responses to MSX2 overexpression using reporter assay. MSX2 overexpression significantly enhanced the NODAL promoter activity in both HEK293T cells and hESCs in a dose-dependent manner (Figure 7G and Supplementary information, Figure S8B). Bioinformatics analysis predicted three potential MSX2-binding sequences (MBS1-3) within the 5 kb region of NODAL promoter (Supplementary information, Figure S8C). ChIP-qPCR analysis in H1 hESCs revealed that MSX2 directly bound to MBS1 and MBS2 of NODAL promoter (Figure 7H). Consistent with its lack of function, MSX2-Δ132-148 mutant did not have binding activity to the NODAL promoter (Supplementary information, Figure S8D). These data suggest that MSX2 induces NODAL expression by directly binding to and activating the NODAL promoter.
Discussion
This study identifies MSX2 as a master mediator of hPSCs' differentiation to mesendoderm. MSX2 is both necessary and sufficient for mesendoderm differentiation in hPSCs. MSX2 is a direct target of BMP signaling in hPSCs, and it is also synergistically activated by Wnt signals via LEF1 during mesendoderm differentiation. Mechanistically, MSX2 binds to SOX2 promoter and inhibits SOX2 transcription, thus destabilizing the pluripotency circuitry. Interestingly, SOX2 can antagonize the function of SOX2 by promoting MSX2 degradation. Furthermore, MSX2 induction of mesendoderm differentiation not only requires SOX2 suppression but also involves activation of Nodal signaling. Our results provide conclusive evidence that MSX2 is a key determinant of hPSC mesendoderm differentiation (Figure 7I). Notably, our results differ from earlier reports that MSX2 is dispensable in early embryonic development26,29. The lack of phenotype in MSX2 deletion is not due to functional redundancy of MSX1 and MSX2, because MSX1/MSX2 double knockout mice form embryonic germ layers normally45,63. The discrepancy between the human and the mouse studies is likely due to the distinct function of MSX2 in the two species. Similar species-specific functions of cell fate-specifying factors have been reported previously. For example, Zhang et al.64 demonstrated that PAX6 is a key determinant of neuroectoderm cell fate in hPSCs but is not involved in mouse neuroectoderm specification.
Among various developmental pathways, the BMP pathway has profound roles in directed differentiation of hPSCs to the early embryonic lineages such as mesendoderm16,23. Despite these critical functions, the direct target genes of BMP signaling that mediate mesendoderm differentiation remain elusive in hPSCs. In this study, we show that expression of MSX2 is induced within 3 h after the addition of BMP4, much more early than T and CDX2, two previously reported downstream effectors of BMP signaling in hESCs48. We show that Smad1 can bind to the phylogenetically conserved BMP-responsive region within the MSX2 promoter in hESCs. Thus, MSX2 can directly respond to BMP signaling in hPSCs to mediate BMP functions in mesendoderm induction. Furthermore, MSX2 not only responds more quickly to BMP4 stimulation than T, but also functions upstream of T during mesendoderm induction of hESCs — overexpression of MSX2 induces T expression, whereas MSX2 depletion prevents T induction. These results together indicate that MSX2 is an early and direct target of BMP in hPSC mesendoderm differentiation. In addition to BMP, MSX2 expression can be further enhanced by Wnt signals via LEF1, likely by cooperating with phosphorylated Smads as previously reported in mouse ESCs51. This latter result suggests that MSX2 acts as a central signaling molecule integrating multiple extrinsic signals during hPSC mesendoderm induction.
How does MSX2 mediate mesendoderm differentiation? We provide evidence for SOX2 as a direct downstream target of MSX2 in hESCs during mesendoderm induction. MSX2 overexpression rapidly reduces the level of SOX2 mRNA and protein. At the mechanistic level, MSX2 directly binds to MBS2 and MBS3 within the SOX2 promoter, leading to inhibition of SOX2 transcription. This transcriptional repressor function of MSX2 is crucial for hESC mesendoderm differentiation:deletion mutant (MSX2-Δ132-148), which lacks suppressor activity, also fails to induce mesendoderm differentiation. The link between MSX2 and SOX2 allows us to postulate a mechanism by which BMP signaling can destabilize the pluripotency state. We envision that MSX2, once activated by mesendoderm-inducing cues such as BMPs, represses SOX2 transcription, thus leading to a perturbation of the pluripotency circuitry and exit of hPSCs from the pluripotent state. In addition, the continuous suppression of SOX2 by MSX2 is likely needed for the inhibition of neuroectoderm activity during differentiation, thus allowing hPSC differentiation to be restricted to mesendoderm. In support of this notion, depletion of SOX2 disrupts pluripotency and induces mesendoderm differentiation of hPSCs.
Interestingly, although SOX2 depletion induces mesendoderm in hPSCs, the upregulation of mesendoderm markers is much less rapid and drastic than by enforced MSX2 expression. Thus, suppression of SOX2 expression by MSX2 cannot fully recapitulate the ability of MSX2 to induce mesendoderm differentiation in hPSCs. By applying a functional genomics approach, we identify NODAL as a novel direct downstream target gene of MSX2 essential for mesendoderm differentiation. In this scenario, BMP and Wnt trigger MSX2 expression, which in turn induces NODAL expression via direct binding and activation of its promoter activity. Multiple studies have shown that BMP, Wnt and NODAL can regulate each other and form a signaling network essential for early lineage specification of mouse and human embryonic stem cells21,61. However, how BMP and Wnt regulate NODAL expression during different development stages is still being defined. Here, we present evidence that MSX2 mediates BMP and Wnt regulation of NODAL function in hESCs during early lineage specification. Although Nodal addition alone has little effect on hPSCs under self-renewal condition, it drastically enhances the effect of SOX2 depletion on hESC mesendoderm differentiation. The differential effects of NODAL in cells with or without SOX2 depletion are reminiscent of previous findings that Nodal/Activin signaling supports pluripotency in the presence of bFGF but induces mesendoderm differentiation when bFGF is removed17,20.
Importantly, SOX2 does not simply lie downstream of MSX2 but can also inhibit the function of MSX2 by reducing the level of MSX2 protein. We further show that SOX2 promotes MSX2 protein degradation via a MG132-sensitive proteasomal pathway. Interestingly, SOX2 fails to decrease the level of MSX2-Δ132-148 mutant protein suggesting the deleted amino acids are not only required for the core suppressor function of MSX2 but also mediate MSX2 degradation. We envision that the mutual antagonism between the two key lineage-specifying factors plays a significant role in fate determination in hPSCs. MSX2 suppression of SOX2 is essential for mesendoderm differentiation. Conversely, SOX2 inhibition of MSX2 contributes to the surveillance of pluripotency, and promotes neuroectoderm differentiation of hPSCs when MSX2 expression is downregulated. Our findings add to emerging evidence that mutual repression between cell-fate regulators represents a key mechanism for governing fate decisions of stem cells. For example, mutual antagonism between OCT4 and CDX2 determines the segregation of the inner cell mass (ICM) and trophectoderm65, while NANOG and GATA6 antagonize each other to control ICM cell fate transition to epiblast or the primitive endoderm66. Notably, mutual repression between OCT4 and CDX2 occurs at the transcriptional level, while MSX2 and SOX2 cross-inhibition exhibits a more complex pattern, occurring at the transcriptional and the protein level.
Materials and Methods
Cell culture
H1 and H9 hESCs (passage 30-60) were purchased from the WiCell Research Institute (Madison, WI, USA) and maintained and expanded in mTeSR1 medium (StemCell Technologies), or E8 medium (Gibco), or MEF-CM changed daily. For differentiation, cells were grown in custom mTeSR1 medium (StemCell Technologies) with or without selected factors as described in the figure legends. NTERA-2 cells were obtained from American Type Culture Collection (ATCC) and cultured according to ATCC's recommendation. The culture medium consists of 10% fetal bovine serum (ATCC). HEK293T cells (ATCC) were cultured according to ATCC recommended protocol. For additional details, see Supplementary information, Data S1.
Lentivirus production and hESC infection
Lentiviruses for gene knockdown or overexpression were packaged using Viralpower Lentivirus Packaging System (Invitrogen) according to the manufacturer's instruction. To infect hESCs, lentiviruses were mixed with mTeSR1 medium, and the mixture was incubated with H1 or H9 cells (∼1 × 105 cells) for 24 h. A multiplicity of infection of 100 was used. To improve the efficiency of infection, 3 μg/ml polybrene (Sigma) was added to the infection medium. To establish hESC stable line with inducible gene expression, Lenti-X™ Tet-On Advanced Inducible Expression System (Clontech) was used following the manufacturer's instruction. For additional details, see Supplementary information, Data S1.
Teratoma formation in SCID mice
All mice used in this study were maintained under specific pathogen-free conditions and all procedures have been approved by the Peking Union Medical College Institutional Animal Care and Use Committee. H1 hESCs containing GFP-MSX2 or GFP inducible expression vectors were harvested and subcutaneously injected into the hind leg region of SCID mice. For additional details, see Supplementary information, Data S1.
Western blotting
For protein analysis, 5 × 106 cells were lysed directly in 200 μl laemmli sample buffer (BioRad). Dilutions for various antibodies were described in Supplementary information, Table S4. The blots were developed using Super-Signal West Pico Chemiluminescent Substrate (Pierce), and signals were quantified with Image J. For additional details, see Supplementary information, Data S1.
Real-time PCR
Total RNA was extracted with Trizol (Invitrogen) following the protocol provided by the manufacturer. Samples were treated with DNase, and the RNA was purified using RNeasy mini kit (Qiagen). cDNA was produced using a reverse transcription system from Promega. All real-time PCR assays were performed with QuantiTech SYBR Green PCR kit (Qiagen) using an ABI PRISM 7900 (Applied Biosystems) following manufacturer's instructions. The primers used are as described in Supplementary information, Table S5.
Reporter assay
Human MSX2 2 kb fragment (−4403 to −2335) containing BMPre, human SOX2gene fragment containing −2000 to +231, and human NODAL gene fragment containing −4862 to +186 were amplified from genomic DNA of H1 hESCs and cloned into pGL4.2 or pGL3 basic vector (Promega).
Details for the construction of pBMPre-LUC, pSOX2-LUC, deletion mutants, MSX2 binding-site mutants, and pNODAL-LUC are available in Supplementary information, Data S1. Cell transfection and cell lysate preparation were performed as described in Supplementary information, Data S1. Firefly luciferase and Renilla luciferase activities were analyzed using a Synergy H4 hybrid Reader (BioTek) according to manufacturer's instruction (Promega). For additional details, see Supplementary information, Data S1.
Chromatin immunoprecipitation (ChIP)
ChIP and quantitative PCR were performed following standard methods. For MSX2 binding sites on SOX2 promoter or NODAL promoter, H1 hESCs overexpressing GFP-FLAG-MSX2 or GFP-FLAG-MSX2-Δ132-148 were crosslinked with 1% formaldehyde at 37 °C for 10 min. For SMAD binding sites on MSX2, H1 hESCs were cultured in custom mTeSR1 medium with 20 ng/ml BMP4 for 6 h prior to fixation. Antibodies and primers are detailed in Supplementary information, Table S7. Values obtained from immunoprecipitated samples are normalized to that of their corresponding input samples. Data are representative of three separate experiments, and error bars indicate mean ± SEM.
Statistical analysis
All data are presented as mean ± SEM. Student's t-test was used to compare two experimental groups, assuming unequal variances. Differences are considered significant when P < 0.05.
Accession number
The RNA-Seq data have been deposited in NCBI (accession number: SRP055541).
References
Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145–1147.
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917–1920.
Rossant J . Stem cells and early lineage development. Cell 2008; 132:527–531.
Yamanaka S . A fresh look at iPS cells. Cell 2009; 137:13–17.
Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122:947–956.
Dalton S . Signaling networks in human pluripotent stem cells. Curr Opin Cell Biol 2013; 25:241–246.
Vallier L, Mendjan S, Brown S, et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 2009; 136:1339–1349.
James D, Levine AJ, Besser D, Hemmati-Brivanlou A . TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005; 132:1273–1282.
Armstrong L, Hughes O, Yung S, et al. The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 2006; 15:1894–1913.
Zhou J, Su P, Wang L, et al. mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc Natl Acad Sci USA 2009; 106:7840–7845.
Singh AM, Reynolds D, Cliff T, et al. Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012; 10:312–326.
Lian X, Zhang J, Zhu K, Kamp TJ, Palecek SP . Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition. Stem Cell 2013; 31:447–457.
Woll PS, Morris JK, Painschab MS, et al. Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells. Blood 2008; 111:122–131.
Vijayaragavan K, Szabo E, Bosse M, Ramos-Mejia V, Moon RT, Bhatia M . Noncanonical Wnt signaling orchestrates early developmental events toward hematopoietic cell fate from human embryonic stem cells. Cell Stem Cell 2009; 4:248–262.
Xu RH, Chen X, Li DS, et al. BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol 2002; 20:1261–1264.
Zhang P, Li J, Tan Z, et al. Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells. Blood 2008; 111:1933–1941.
Vallier L, Alexander M, Pedersen RA . Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 2005; 118:4495–4509.
Beattie GM, Lopez AD, Bucay N, et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cell 2005; 23:489–495.
Ramos-Mejia V, Melen GJ, Sanchez L, et al. Nodal/Activin signaling predicts human pluripotent stem cell lines prone to differentiate toward the hematopoietic lineage. Mol Ther 2010; 18:2173–2181.
Brown S, Teo A, Pauklin S, et al. Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cell 2011; 29:1176–1185.
Chng Z, Teo A, Pedersen RA, Vallier L . SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells. Cell Stem Cell 2010; 6:59–70.
Zhou J, Su P, Li D, Tsang S, Duan E, Wang F . High-efficiency induction of neural conversion in human ESCs and human induced pluripotent stem cells with a single chemical inhibitor of transforming growth factor beta superfamily receptors. Stem Cell 2010; 28:1741–1750.
Richter A, Valdimarsdottir L, Hrafnkelsdottir HE, et al. BMP4 promotes EMT and mesodermal commitment in human embryonic stem cells via SLUG and MSX2. Stem Cell 2014; 32:636–648.
Bell JR, Noveen A, Liu YH, et al. Genomic structure, chromosomal location, and evolution of the mouse Hox 8 gene. Genomics 1993; 17:800.
Davidson D . The function and evolution of Msx genes: pointers and paradoxes. Trends Genet 1995; 11:405–411.
MacKenzie A, Ferguson MW, Sharpe PT . Expression patterns of the homeobox gene, Hox-8, in the mouse embryo suggest a role in specifying tooth initiation and shape. Development 1992; 115:403–420.
Li Y, Liu J, Hudson M, Kim S, Hatch NE . FGF2 promotes Msx2 stimulated PC-1 expression via Frs2/MAPK signaling. J Cell Biochem 2010; 111:1346–1358.
Newberry EP, Latifi T, Battaile JT, Towler DA . Structure-function analysis of Msx2-mediated transcriptional suppression. Biochemistry 1997; 36:10451–10462.
Satokata I, Ma L, Ohshima H, et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 2000; 24:391–395.
Ma L, Golden S, Wu L, Maxson R . The molecular basis of Boston-type craniosynostosis: the Pro148-->His mutation in the N-terminal arm of the MSX2 homeodomain stabilizes DNA binding without altering nucleotide sequence preferences. Hum Mol Genet 1996; 5:1915–1920.
Garcia-Minaur S, Mavrogiannis LA, Rannan-Eliya SV, et al. Parietal foramina with cleidocranial dysplasia is caused by mutation in MSX2. Eur J Hum Genet 2003; 11:892–895.
Jabs EW, Muller U, Li X, et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 1993; 75:443–450.
Wuyts W, Reardon W, Preis S, et al. Identification of mutations in the MSX2 homeobox gene in families affected with foramina parietalia permagna. Hum Mol Genet 2000; 9:1251–1255.
Quinn LM, Latham SE, Kalionis B . The homeobox genes MSX2 and MOX2 are candidates for regulating epithelial-mesenchymal cell interactions in the human placenta. Placenta 2000; 21 Suppl A:S50–54.
di Bari MG, Ginsburg E, Plant J, Strizzi L, Salomon DS, Vonderhaar BK . Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1. J Cell Physiol 2009; 219:659–666.
Friedmann Y, Daniel CW . Regulated expression of homeobox genes Msx-1 and Msx-2 in mouse mammary gland development suggests a role in hormone action and epithelial-stromal interactions. Dev Biol 1996; 177:347–355.
Xia X, Ayala M, Thiede BR, Zhang SC . In vitro- and in vivo-induced transgene expression in human embryonic stem cells and derivatives. Stem Cells 2008; 26:525–533.
Suzuki A, Ueno N, Hemmati-Brivanlou A . Xenopus msx1 mediates epidermal induction and neural inhibition by BMP4. Development 1997; 124:3037–3044.
Bei M, Maas R . FGFs and BMP4 induce both Msx1-independent and Msx1-dependent signaling pathways in early tooth development. Development 1998; 125:4325–4333.
Evseenko D, Zhu Y, Schenke-Layland K, et al. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc Natl Acad Sci USA 2010; 107:13742–13747.
Mendjan S, Mascetti VL, Ortmann D, et al. NANOG and CDX2 pattern distinct subtypes of human mesoderm during exit from pluripotency. Cell Stem Cell 2014; 15:310–325.
Yu P, Pan G, Yu J, Thomson JA . FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell 2011; 8:326–334.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8:2281–2308.
Fu H, Ishii M, Gu Y, Maxson R . Conditional alleles of Msx1 and Msx2. Genesis 2007; 45:477–481.
Nieminen P, Arte S, Pirinen S, Peltonen L, Thesleff I . Gene defect in hypodontia: exclusion of MSX1 and MSX2 as candidate genes. Hum Genet 1995; 96:305–308.
Vieux-Rochas M, Bouhali K, Mantero S, et al. BMP-mediated functional cooperation between Dlx5;Dlx6 and Msx1;Msx2 during mammalian limb development. PLoS One 2013; 8:e51700.
Qadir AS, Lee HL, Baek KH, et al. Msx2 is required for TNF-alpha-induced canonical Wnt signaling in 3T3-L1 preadipocytes. Biochem Biophys Res Commun 2011; 408:399–404.
Bernardo AS, Faial T, Gardner L, et al. BRACHYURY and CDX2 mediate BMP-induced differentiation of human and mouse pluripotent stem cells into embryonic and extraembryonic lineages. Cell Stem Cell 2011; 9:144–155.
Brugger SM, Merrill AE, Torres-Vazquez J, et al. A phylogenetically conserved cis-regulatory module in the Msx2 promoter is sufficient for BMP-dependent transcription in murine and Drosophila embryos. Development 2004; 131:5153–5165.
Sun J, Ishii M, Ting MC, Maxson R . Foxc1 controls the growth of the murine frontal bone rudiment by direct regulation of a Bmp response threshold of Msx2. Development 2013; 140:1034–1044.
Hussein SM, Duff EK, Sirard C . Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. J Biol Chem 2003; 278:48805–48814.
Fong H, Hohenstein KA, Donovan PJ . Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cell 2008; 26:1931–1938.
Graham V, Khudyakov J, Ellis P, Pevny L . SOX2 functions to maintain neural progenitor identity. Neuron 2003; 39:749–765.
Wang Z, Oron E, Nelson B, Razis S, Ivanova N . Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell 2012; 10:440–454.
Lin IY, Chiu FL, Yeang CH, et al. Suppression of the SOX2 neural effector gene by PRDM1 promotes human germ cell fate in embryonic stem cells. Stem Cell Rep 2014; 2:189–204.
Lengler J, Bittner T, Munster D, Gawad Ael D, Graw J . Agonistic and antagonistic action of AP2, Msx2, Pax6, Prox1 AND Six3 in the regulation of Sox2 expression. Ophthalmic Res 2005; 37:301–309.
Tomioka M, Nishimoto M, Miyagi S, et al. Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res 2002; 30:3202–3213.
Twizere JC, Lefebvre L, Collete D, et al. The homeobox protein MSX2 interacts with tax oncoproteins and represses their transactivation activity. J Biol Chem 2005; 280:29804–29811.
Yoon WJ, Cho YD, Cho KH, et al. The Boston-type craniosynostosis mutation MSX2 (P148H) results in enhanced susceptibility of MSX2 to ubiquitin-dependent degradation. J Biol Chem 2008; 283:32751–32761.
Arnold SJ, Robertson EJ . Making a commitment: cell lineage allocation and axis patterning in the early mouse embryo. Nat Rev Mol Cell Biol 2009; 10:91–103.
Schier AF, Shen MM . Nodal signalling in vertebrate development. Nature 2000; 403:385–389.
Sumi T, Tsuneyoshi N, Nakatsuji N, Suemori H . Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling. Development 2008; 135:2969–2979.
Lallemand Y, Nicola MA, Ramos C, Bach A, Cloment CS, Robert B . Analysis of Msx1; Msx2 double mutants reveals multiple roles for Msx genes in limb development. Development 2005; 132:3003–3014.
Zhang X, Huang CT, Chen J, et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell 2010; 7:90–100.
Suwinska A, Czolowska R, Ozdzenski W, Tarkowski AK . Blastomeres of the mouse embryo lose totipotency after the fifth cleavage division: expression of Cdx2 and Oct4 and developmental potential of inner and outer blastomeres of 16- and 32-cell embryos. Dev Biol 2008; 322:133–144.
Bessonnard S, De Mot L, Gonze D, et al. Gata6, Nanog and Erk signaling control cell fate in the inner cell mass through a tristable regulatory network. Development 2014; 141:3637–3648.
Acknowledgements
This work was supported by the National Basic Research Program of China (2012CB966403 and 2015CB964902 to JZ), the National Natural Science Foundation of China (31171431 to JZ, 31301206 to YB and 81370600 to DL) and Tianjin Natural Science Foundation (11JCYBJC27300 to JZ). We thank Drs. Tao Cheng, Dangsheng Li and Lihong Shi for their suggestions during manuscript preparation. We thank members of the Zhou lab for their insightful discussion during the course of this work. We thank Drs Xiaoqing Zhang and Baoyang Hu for providing plasmids for this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
( Supplementary information is linked to the online version of the paper on the Cell Research website.)
Supplementary information
Supplementary information, Figure S1
MSX2 suffices to induce hESC mesendoderm differentiation. (PDF 394 kb)
Supplementary information, Figure S2
hESCs monolayer mesendoderm differentiation model was established successfully. (PDF 281 kb)
Supplementary information, Figure S3
MSX2 is necessary for hESC mesendoderm specification. (PDF 345 kb)
Supplementary information, Figure S4
MSX2 is knockout in hESCs successfully and MSX2 suppresses SOX2 expression by direct binding to its promoter. (PDF 279 kb)
Supplementary information, Figure S5
MSX2 suppression of SOX2 is linked to its mesendoderm-inducing function. (PDF 417 kb)
Supplementary information, Figure S6
SOX2 rescues MSX2 mesendoderm induction by promoting its degradation. (PDF 430 kb)
Supplementary information, Figure S7
Nodal signaling is an essential downstream effector of MSX2. (PDF 320 kb)
Supplementary information, Figure S8
MSX2 induces NODAL expression by directly binding to and activating the NODAL promoter. (PDF 134 kb)
Supplementary information, Data S1
Material & Methods (PDF 203 kb)
Supplementary information, Table S1
The soluble factors used in this paper (PDF 58 kb)
Supplementary information, Table S2
The primers used for amplifying genes (PDF 100 kb)
Supplementary information, Table S3
The primers used for CRISPR sgRNA guide sequences and the genotyping (PDF 53 kb)
Supplementary information, Table S4
Sources and dilutions of the antibodies (PDF 53 kb)
Supplementary information, Table S5
The primers used for real-time PCR (PDF 103 kb)
Supplementary information, Table S6
The primers used for amplifying gene fragment and luciferase reporter plasmids construct (PDF 56 kb)
Supplementary information, Table S7
The primers used for PCR after ChIP (PDF 57 kb)
Rights and permissions
About this article
Cite this article
Wu, Q., Zhang, L., Su, P. et al. MSX2 mediates entry of human pluripotent stem cells into mesendoderm by simultaneously suppressing SOX2 and activating NODAL signaling. Cell Res 25, 1314–1332 (2015). https://doi.org/10.1038/cr.2015.118
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cr.2015.118
- Springer Nature Singapore Pte Ltd.
Keywords
This article is cited by
-
The benign nature and rare occurrence of cardiac myxoma as a possible consequence of the limited cardiac proliferative/ regenerative potential: a systematic review
BMC Cancer (2023)
-
CAR-NK cells for cancer immunotherapy: from bench to bedside
Biomarker Research (2022)
-
Systematic comparation of the biological and transcriptomic landscapes of human amniotic mesenchymal stem cells under serum-containing and serum-free conditions
Stem Cell Research & Therapy (2022)
-
Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance
Cell Death & Differentiation (2022)
-
Pluripotent-derived Mesenchymal Stem/stromal Cells: an Overview of the Derivation Protocol Efficacies and the Differences Among the Derived Cells
Stem Cell Reviews and Reports (2022)